Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
2008 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Cancer statistics, 2022
2022 Standout
High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis
2019
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression
2019 Standout
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
2006
Analysis of the genome to personalize therapy for melanoma
2010
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
2017
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma
2016
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
2008
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
2014
Ovarian cancer
2014 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Perifosine: Update on a novel Akt inhibitor
2009
Macrophages in immunoregulation and therapeutics
2023 Standout
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
2017
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
The Role of PPARγReceptors and Leukotriene B4Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer
2008
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Akt inhibitors in clinical development for the treatment of cancer
2010
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
2007
Multi-targeted therapy of cancer by genistein
2008 Standout
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
2007
Eicosanoids and cancer
2010 Standout
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
2008
Metabolic reprogramming in macrophage responses
2021
Akt signalling in health and disease
2011 Standout
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
2011
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma
2008
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
2007
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Real-World Evidence — What Is It and What Can It Tell Us?
2016 Standout
Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis
2007
Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy
2008
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Breast Cancer Statistics, 2022
2022 Standout
The Pharmacology of mTOR Inhibition
2009 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
2021
Comparative toxicities of 3 platinum‐containing chemotherapy regimens in relapsed/refractory lymphoma patients
2016
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
2007
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
2021
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression
2015
Parellel inhibition of LH-RH-induced cyclic AMP accumulation and LH and FSH release by LH-RH antagonists in vitro.
1975 StandoutNobel
Works of Tara Baetz being referenced
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma
2004
Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
2003
A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma
2018
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours
2006
Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12
2015
Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma
2005
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
2015
Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer
2012
Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
2005
Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.
2011
Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma
2021
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
2015